Effects of ageing on pro-arrhythmic ventricular phenotypes in incrementally paced murine Pgc-1β−/− hearts

Shiraz Ahmad 1 · Haseeb Valli 1 · Charlotte E. Edling 2 · Andrew A. Grace 3 · Kamalan Jeevaratnam 1, 2, 4 · Christopher L-H Huang 1, 3

Received: 14 July 2017 / Revised: 2 August 2017 / Accepted: 3 August 2017 / Published online: 18 August 2017
© The Author(s) 2017. This article is an open access publication

Abstract A range of chronic clinical conditions accompany cardiomyocyte energetic dysfunction and constitute independent risk factors for cardiac arrhythmia. We investigated pro-arrhythmic and arrhythmic phenotypes in energetically deficient C57BL mice with genetic ablation of the mitochondrial promoter peroxisome proliferator-activated receptor-γ coactivator-1β (Pgc-1β), a known model of ventricular arrhythmia. Pro-arrhythmic and cellular action potential (AP) characteristics were compared in intact Langendorff-perfused hearts from young (12–16 week) and aged (> 52 week), wild-type (WT) and Pgc-1β−/− mice. Simultaneous electrocardiographic and intracellular microelectrode recordings were made through successive trains of 100 regular stimuli at progressively incremented heart rates. Aged Pgc-1β−/− hearts displayed an increased incidence of arrhythmia compared to other groups. Young and aged Pgc-1β−/− hearts showed higher incidences of alternans in both AP activation (maximum AP upshoot velocity (dV/dt)max and latency), recovery (action potential duration (APD90) and resting membrane potential (RMP) characteristics compared to WT hearts. This was particularly apparent at lower pacing frequencies. These findings accompanied reduced (dV/dt)max and increased AP latency values in the Pgc-1β−/− hearts. APs observed prior to termination of the protocol showed lower (dV/dt)max and longer AP latencies, but indistinguishable APD90 and RMPs in arrhythmic compared to those in non-arrhythmic hearts. APD restitution analysis showed that Pgc-1β−/− and WT hearts showed similar limiting gradients. However, Pgc-1β−/− hearts had shortened plateau AP wavelengths, particularly in aged Pgc-1β−/− hearts. Pgc-1β−/− hearts therefore show pro-arrhythmic instabilities attributable to altered AP conduction and activation rather than recovery characteristics.

Keywords Peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) · Ventricles · Action potential · Wavelength · Cardiac conduction · Cardiac arrhythmias

Introduction

Following the successful mechanistic and mathematical description of the cardiac action potential and its propagation, cardiac electrophysiology has increasingly focused upon the physiological mechanisms underlying arrhythmia [19]. The risk of cardiac rhythm abnormalities accumulates with age. The prevalence of atrial fibrillation rises from ~ 4% of individuals aged 60–70 to ~ 20% at > 80 years [54], while the incidence of sudden cardiac death attributable to ventricular arrhythmias is eight times higher in 75- than 50-year-old individuals [8]. Metabolic abnormalities associated with chronic, age-dependent, conditions including obesity, insulin resistance, diabetes mellitus and heart failure also accentuate arrhythmic risk, independently of any ischaemic changes arising from associated coronary vascular effects [1, 28, 51]. These situations are accompanied by cardiomyocyte energetic and therefore, mitochondrial dysfunction, itself an independent arrhythmogenic risk factor [2]. Thus, inherited mitochondrial
disorders such as Kearns-Sayre syndrome predispose to fatal ventricular arrhythmias [24]. Fibrotic defects of the cardiac conduction system leading to heart block are similarly age-related and contribute to age-dependent onsets of inherited arrhythmic conditions including the Brugada syndrome [22].

The peroxisome proliferator-activated receptor-γ coactivator-1 (PGC-1) family of transcriptional coactivators offers a strategic target for studying the electrophysiological consequences of energetic deficiency. PGC-1 regulates mitochondrial mass, function and cellular metabolism [13], upregulating nuclear and mitochondrial gene expression involved in fatty acid β-oxidation, the tricarboxylic acid cycle and the electron transport chain [3]. PGC-1 protein expression and, correspondingly, mitochondrial activity vary with upstream cellular energy demand [44]. Metabolic conditions such as obesity, insulin resistance and type II diabetes as well as advanced age are associated with reduced PGC-1 protein expression and mitochondrial dysfunction [9, 30, 36].

Much of the biochemical insight into the consequences of cardiac energetic deficiency [21, 38] derives from studies in hearts with dysfunctional PGC-1 networks [4, 20]. Pgc-1α−/− murine hearts show normal baseline contractility, developing heart failure only with increased afterload [3]. Pgc-1β−/− hearts similarly show normal baseline cardiac function, but display compromised heart rate responses with adrenergic stimulation [29]. Langendorff-perfused Pgc-1β−/− hearts demonstrated preliminary evidence for increased arrhythmogenicity. Their isolated cardiomyocytes showed diastolic Ca2+ transients, afterdepolarisation events and altered ion channel expression patterns [17], abnormalities also known to occur with ageing [18].

The combination of normal contractile function with proarrhythmic electrophysiological changes suggests that Pgc-1β−/− hearts are suitable models to explore the proarrhythmic effects of mitochondrial impairment. Isolated, perfused, murine hearts have proved to be useful in the study of arrhythmic phenotypes and their underlying mechanisms. They have been particularly important in studies of specific genetic modifications directed at well-defined, inherited, monogenic ion channelopathies [19, 22, 25]. The present study extends these analyses to Pgc-1β−/− hearts through the analysis of the electrophysiological consequences of energetic dysfunction. Chronic mitochondrial lesions likely exert cumulative and time-varying phenotypic effects with advancing age, and so the experiments studied both young and aged, wild-type (WT) and genetically modified animals.

Methods

Animals

This research has been regulated under the Animals (Scientific Procedures) Act 1986 Amendment Regulations 2012 following ethical review by the University of Cambridge Animal Welfare and Ethical Review Body (AWERB). The experiments also conformed to the Guide for the Care and Use of Laboratory Animals, U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996). Mice were housed in an animal facility at 21 °C with 12-h light/dark cycles. Animals were fed sterile chow (RM3 Maintenance Diet; SDS, Witham, Essex, UK) and had free access to water, bedding and environmental stimuli. Mice were sacrificed by cervical dislocation. No recovery, anaesthetic or surgical procedures were required. Wild-type (WT) C57/B6 and Pgc-1β−/− adult mice were bred for the experimental protocols. Pgc-1β−/− mice were generated as described previously [17, 29]. Briefly, a triple LoxP targeting vector was used, containing a floxed neomycin phosphotransferase selectable marker cassette inserted into intron 3 and a single LoxP site inserted into intron 5. This resulted in the deletion of exons 4 and 5. The presence of LoxP sites was confirmed in embryonic stem cells using Southern blot analysis. Heterozygous triple LoxP mice crossed with ROSA26-Cre mice generated heterozygous Pgc-1β−/− mice, which were further bred to generate homozygous Pgc-1β−/− mice. Mice were bred on a C57/B6 background to avoid possible strain-related confounds. Experiments were performed in four experimental groups: young WT (n = 23), young Pgc-1β−/− (n = 21), aged WT (n = 19) and aged Pgc-1β−/− (n = 25). All young mice were aged between 12 and 16 weeks and aged mice greater than 52 weeks.

Buffering media

All solutions used were based on Krebs–Henseleit (KH) solution (mM: NaCl, 119; NaHCO3, 25; KCl, 4.0; KH2PO4, 1.2; MgCl2, 1.0; CaCl2, 1.8; glucose, 10; and Na-pyruvate, 2.0; pH adjusted to 7.4 and bubbled with 95% O2/5% CO2 (British Oxygen Company, Manchester, UK). Chemical agents were purchased from Sigma-Aldrich (Poole, UK). A modified KH solution containing KH mixed with 20 μM blebbistatin (Selleckchem, Suffolk, UK) [10–12, 23] was used for perfusion to immobilise hearts prior to plain Krebs–Henseleit perfusion.

Whole-heart intracellular microelectrode recordings

Prior to sacrifice, 200 IU of unfractionated heparin (Sigma-Aldrich, Poole, UK) was administered intraperitoneally. Animals were then sacrificed and rapid sternectomy and cardiectomy were performed. All hearts were macroscopically unremarkable with no obvious abnormalities. Hearts were rapidly cannulated and secured as previously described [33, 39, 52] before being mounted on a horizontal Langendorff apparatus that was electrically insulated and incorporated into an intracellular rig within a Faraday cage, incorporating a light microscope (objective ×5, eyepiece ×5; W. Watson and Sons Limited, London, UK), organ bath and custom-built microelectrode amplifier and head stage.
Hearts were mounted in a standard anatomical position to allow impalement of the left ventricular mass and pacing from the right ventricle simultaneously. The positioning of the recording and stimulating electrodes was controlled by two precision micromanipulators (Prior Scientific Instruments, Cambs., UK), calibrated to permit impalements over the same region of the myocardium. Stimulating and recording electrodes were positioned at consistent sites against the lateral surface of the right ventricle and the proximal left ventricle respectively to avoid confounds of regional differences in action potential (AP) characteristics. Accordingly, in any given experiment, alterations in AP latencies, measured as the time elapsed between the pacing stimulus and peak of the AP, reflected alterations in AP conduction velocities. Hearts were perfused with KH solution (at a constant flow rate of 2.1 ml min$^{-1}$) for at least 5 min to reach steady state, before being perfused with KH solution and 20 μM blebbistatin to minimise motion, before resumption of perfusion with plain KH solution. Preparations which did not show a regular intrinsic rhythm with a basic cycle length (BCL) of <200 ms and 1:1 atrioventricular (AV) conduction for > 10-min post-canulation were not studied further. A conventional sharp 3-M KCl-filled microelectrode (tip resistance 15–25 MΩ, filled with 3 M KCl) was pulled by a custom-built microelectrode puller from a glass pipette (1.2 mm OD, 0.69 mm ID; Harvard Apparatus) and then inserted into a right-angled microelectrode holder (Harvard Apparatus, Kent, UK). This was connected to the headstage of a high-input impedance direct-current microelectrode amplifier system (University of Cambridge, Cambridge, UK). Following band-pass filtering between 0 and 2 kHz and amplification, the signal was passed through an analogue to digital converter at a sampling frequency of 10 kHz (1401; Cambridge Electronic Design). Data was captured with Spike2 software (Cambridge Electronic Design) and then analysed using a custom-written program using the python programming language. Alternans was defined as beat to beat changes in the value of a parameter such that the direction of the change oscillates for at least ten successive action potentials. All statistical analysis was carried out using the R programming language [40] and plots with the grammar of graphics package [49]. All data is expressed as mean ± standard error of mean (SEM) and a p value of less than 0.05 taken to be significant. The different experimental groups were compared with a two-factor analysis of variance (ANOVA). F values that were significant for interactive effects prompted post hoc testing with Tukey honestly significant difference testing. If single comparisons were made, a two-tailed Student’s t test was used to compare significance. Categorical variables were compared using Fisher’s exact test. Kaplan-Meier estimates were compared with the log-rank test.

**Whole-heart electrocardiographic recordings**

Electrocardiographic (ECG) recordings of isolated Langendorff-perfused hearts were obtained simultaneously with intracellular microelectrode measurements to enable correlations between whole-organ rhythms and intracellular voltage changes. Recordings were made using two unipolar ECG electrodes placed at fixed positions around the heart in the organ bath, corresponding to the standard three-lead ECG coordinates. The recorded signals were passed through headstages for pre-amplification, prior to amplification (Neurolog NL104 amplifier) and band-pass filtering (between 5 and 500 Hz; NL 125/6 filter; Digitimer, Herts, UK) before being digitized at a sampling frequency of 10 kHz (1401; Cambridge Electronic Design).

**Pacing protocols**

Hearts were stimulated at two times the threshold voltage plus 0.5 mV. Hearts underwent two pacing protocols. A standardised S1S2 protocol consisted of trains of eight stimuli delivered 125 ms apart (S1 stimuli) followed by an extrasystolic (S2) stimulus delivered initially at 90 ms after the previous S1 stimulus. This pattern of stimulation was repeated with the S2-S1 interval decremented by 1 ms for each successive cycle until failure of capture. Incremental pacing protocols began at a 130 ms basic cycle length (BCL) before being decremented by 5 ms for each subsequent cycle of 100 stimulations. This cycle was repeated until the heart showed entry into 2:1 block or arrhythmia.

**Data and statistical analysis**

Data was captured with Spike2 software (Cambridge Electronic Design) and then analysed using a custom-written program using the python programming language. Alternans was defined as beat to beat changes in the value of a parameter such that the direction of the change oscillates for at least ten successive action potentials. All statistical analysis was carried out using the R programming language [40] and plots with the grammar of graphics package [49]. All data is expressed as mean ± standard error of mean (SEM) and a p value of less than 0.05 taken to be significant. The different experimental groups were compared with a two-factor analysis of variance (ANOVA). F values that were significant for interactive effects prompted post hoc testing with Tukey honestly significant difference testing. If single comparisons were made, a two-tailed Student’s t test was used to compare significance. Categorical variables were compared using Fisher’s exact test. Kaplan-Meier estimates were compared with the log-rank test.
in young and aged, WT (57.36 ± 2.06 and 56.3 ± 1.96 ms, respectively) and Pgc-1β−/− (53.99 ± 2.2 and 47.64 ± 1.84 ms, respectively) hearts demonstrated that Pgc-1β−/− hearts showed shorter VERPs than WT hearts (56.88 ± 1.42 vs 50.54 ± 1.48 ms; n = 42 vs 46; p < 0.01), without effects of either age or interactions between age and genotype.

Intracellular microelectrode recordings of cardiomyocyte APs within left ventricular epicardia were then obtained in parallel with ECG recordings of isolated Langendorff hearts during an incremental pacing protocol. Trains of 100 regular stimuli were imposed at BCLs progressively shortened by 5 ms with each successive stimulus train. These were examined for the presence of arrhythmic activity and alternans in AP parameters related to their activation or recovery. Figure 1 tracks the progress of the experiments through the incremental pacing protocol in all the four groups, using Kaplan-Meier plots of the probability of hearts showing regular 1:1 evoked activity with decreasing BCL. Quantitative analysis was performed for BCLs up to 55 ms, after which insufficient hearts showed regular 1:1 capture for analysis. The BCLs at which hearts failed to follow the repetitive pacing and entered 2:1 block reflect their VERP at capture for analysis. The BCLs at which hearts failed to follow the repetitive pacing and entered 2:1 block reflect their VERPs. Figure 2 compares parallel ECG (i) and intracellular AP recordings (ii) of regular ventricular activity at a BCL of 130 ms from a young WT mouse (a). Similar simultaneous ECG (i) and intracellular AP recordings (ii) recordings made it possible to detect ectopic beats (b), monomorphic ventricular tachycardia (VT) (c) and torsades de pointes (TdP) (d) in aged Pgc-1β−/− hearts. Under these experimental conditions, there were no observations of spontaneous or delayed afterdepolarisations. The latter have been reported in other pro-arrhythmic murine systems where they have been implicated in arrhythmic triggering [5, 6, 14].

Table 1 quantifies the occurrence of arrhythmic phenomena in cardiomyocytes from which the intracellular records were obtained. Aged Pgc-1β−/− hearts showed the highest arrhythmic incidences compared to the remaining groups (p < 0.05). The latter groups showed similar, reduced, arrhythmic frequencies. Aged Pgc-1β−/− hearts were also the only experimental group that showed ectopic activity, monomorphic VT and polymorphic VT (Fig. 2b–d). The incidence of arrhythmias in hearts from young Pgc-1β−/− hearts was not distinguishable from their WT counterparts.

Figure 3 exemplifies the different forms of alternans in AP characteristics observed in a typical aged Pgc-1β−/− heart with each panel displaying (from top to bottom) AP waveforms, AP latency (Fig. 4b), AP duration to 90% recovery (APD 90) (Fig. 4c) and resting membrane potential (RMP) (Fig. 4d) in young and aged, WT and Pgc-1β−/− hearts through the incremental pacing protocol described above. Overall incidences of
alternans were obtained for each heart by summing the number of beats of alternans at each BCL examined. The results were then compared between the experimental groups. Pgc-1β−/− hearts showed greater overall incidences of alternans compared to WT hearts in all the parameters (dV/dt)max, AP latency, APD90 and RMP. Thus, both young and aged Pgc-1β−/− hearts displayed an increased tendency to display alternans (Table 2).

Secondly, in addition to the above effects of genotype alone, genotype and age exerted interacting effects on the incidence of AP latency alternans (p < 0.05) and APD90 alternans (p < 0.05). Young WT hearts had the lowest incidences of AP latency alternans (575 ± 51 beats) with progressive increases in this incidence through the series: young Pgc-1β−/− hearts (785 ± 78 beats), aged WT hearts (790 ± 33 beats) and aged Pgc-1β−/− hearts (923 ± 81 beats), with the last group showing the greatest amount of AP latency alternans. Post hoc testing demonstrated significantly more AP latency alternans in young Pgc-1β−/− hearts compared to that in young WT hearts (p < 0.01) and that in aged Pgc-1β−/− hearts compared to that in young WT hearts (p < 0.001). A similar pattern emerged in post hoc testing for APD90 alternans: all remaining groups showed significantly more alternans than young WT hearts (young WT vs young Pgc-1β−/−, 726 ± 65 vs 1068 ± 53 beats, p < 0.001; young WT vs aged WT, 726 ± 65 vs 1040 ± 37 beats, p = 0.001; young WT vs aged Pgc-1β−/−, 726 ± 65 vs 1107 ± 60 beats p < 0.0001).

Alternans at longer BCLs, with longer episodes, and involving multiple AP parameters in Pgc-1β−/− hearts

Figure 4 also displays the distribution of alternans in each parameter across different BCLs for each experimental group. It is apparent that there are greater incidences of alternans at longer BCLs in Pgc-1β−/− hearts than those in WT hearts. This suggests that they have a greater tendency to instability even at lower heart rates. In addition to the absolute burden of alternans described previously, we quantified the number of discrete sequences of alternans per protocol, the maximum

### Table 1 Frequency of arrhythmia in the various experimental groups

|                | Arrhythmic | Non-arrhythmic | Total (n) | Percentage arrhythmic |
|----------------|------------|----------------|----------|-----------------------|
| Young WT       | 4          | 19             | 23       | 17.4                  |
| Aged WT        | 3          | 16             | 19       | 15.8                  |
| Young Pgc-1β−/−| 4          | 17             | 21       | 19.0                  |
| Aged Pgc-1β−/− | 12*        | 13             | 25       | 48*                   |

* p < 0.05
duration of alternans as well as the amount of simultaneous alternans between multiple parameters.

First, there were no distinguishable differences in the number of discrete episodes of alternans in \((dV/dt)_{\text{max}}, \text{APD}_{90}\) or \(\text{RMP}\) between young and aged, \(\text{Pgc-1}^{-/}\) hearts. In contrast, aged \(\text{Pgc-1}^{-/}\) hearts showed a higher number of discrete runs of AP latency alternans than young WT hearts (11.0 ± 1.24 vs 7.43 ± 0.58 runs of alternans; \(p < 0.05\)).

Secondly, the maximum duration of individual alternans episodes, whether involving \((dV/dt)_{\text{max}}, \text{AP latency, APD}_{90}\) or \(\text{RMP}\) between young and aged, \(\text{Pgc-1}^{-/}\) and WT hearts.

![Fig. 3 Examples of alternans phenomena comparing records of AP waveform, AP latency, \((dV/dt)\), \(\text{APD}_{90}\) and RMP respectively in each panel. In a, alternans exclusively involves the recovery variable \(\text{APD}_{90}\) while in b, it involves the activation variables of AP latency and \((dV/dt)\) alone. In c and d, there is simultaneous alternans involving both activation and recovery variables. These include situations in which the alternating action potentials with higher/lower latencies and therefore lower/higher \((dV/dt)_{\text{max}}\) show either higher/lower (c) or lower/higher (d) \(\text{APD}_{90}\), respectively.](image1)

![Fig. 4 Incidence of alternans out of 100 beats at each BCL in the activation variables of maximum AP upstroke rate \((dV/dt)_{\text{max}}\) (a), AP latency (b), and the recovery variables of AP duration to 90% recovery \(\text{APD}_{90}\) (c) and resting membrane potential (RMP) (d) in young and aged, WT and \(\text{Pgc-1}^{-/}\) hearts through the incremental pacing protocol.](image2)
of APD90, (c) RMP (d) and diastolic interval, DI, (given by the time between the action potential peak and the preceding APD90) (e) against BCL in young and aged, Pgc-1β/− and WT hearts. All data varied monotonically with BCL and so their overall magnitudes could be compared by the areas beneath their curves. Table 3 demonstrates that hearts with the Pgc-1β/− genotype have lower (dV/dt)max values and increased AP latencies relative to WT (both p < 0.001). However, there were no detectable effects of either ageing or any interaction between genotype and ageing on (dV/dt)max. In contrast, neither APD90 nor RMPs were influenced by genotype alone. However, APD90 was longer in aged Pgc-1β/− hearts than that in young Pgc-1β/− hearts (p < 0.05), and RMP greater in aged than young hearts.

**Wavelength as the basis for arrhythmic substrate**

The findings above demonstrate pro-arrhythmic features in aged Pgc-1β/− hearts. Further quantification demonstrated increased alternans in both young and aged Pgc-1β/− hearts. This in turn correlated with altered AP activation characteristics as reflected in (dV/dt)max and AP latency, as opposed to the recovery characteristics, APD90 and RMP. The following analyses further tested the hypothesis that activation and not recovery parameters are the primary determinant of arrhythmia in this system.

First, hearts were stratified by arrhythmic and non-arrhythmic phenotypes, regardless of genotype or age. AP parameters observed prior to the onset of either arrhythmia or entry into 2:1 block were then compared. Arrhythmic hearts (n = 20) showed lower (dV/dt)max and longer AP latencies than non-arrhythmic hearts (n = 68) ((dV/dt)max, 67.29 ± 6.85 vs 87.66 ± 3.28 V s⁻¹, p < 0.05; AP latencies 22.25 ± 1.50 vs 18.64 ± 0.88 ms, p < 0.05, respectively). Diastolic interval (D150) durations were calculated from the APD90 time to the next action potential peak; thus, they were consequently altered as expected from the altered AP rise times (27.43 ± 1.53 vs 31.54 ± 1.09 ms; p < 0.05). There were no significant differences between their APD90 (32.75 ± 1.22 and 34.79 ± 0.92 ms) and RMPs (−73.81 ± 1.16 vs
These findings implicate AP activation rather than recovery parameters in the initiation of arrhythmia.

Secondly, previous reports have correlated alternans characteristics to arrhythmic tendency in both monogenic murine models as well as in clinical situations. Arrhythmic syndromes primarily attributed to repolarisation abnormalities, exemplified by the murine $Scn5a^{+/\Delta KPQ}$ model, were associated with alterations in the relationship between APD$_{90}$ and VERP with varying DI [33, 35, 41]. In contrast, arrhythmia attributed to altered conduction in $Scn5a^{+/-}$ hearts was associated with altered relationships between active AP wavelengths, $\lambda$, and BCL [39] or resting wavelength $\lambda_0$ [34]. Figure 6 illustrates the outcome of analyses testing both assumptions. These demonstrated indistinguishable limiting slopes in restitution plots of APD$_{90}$ against DI$_{90}$ in all the four experimental groups (Fig. 6a), in opposition to the prediction from the first hypothesis. We then proceeded to determine $\lambda$, calculated as the product of conduction velocity represented by $1/(\text{AP latency})$ and the corresponding VERP at each BCL. This was derived by interpolating values from the VERP obtained during the S1S2 protocol at a BCL of 125 ms and from the VERP obtained from the BCL during incremental pacing prior to loss of 1:1 stimulus capture. Young and aged WT hearts showed similar $\lambda$-BCL and $\lambda$-$\lambda_0$ plots (Fig. 6b, c). However, $Pgc-1^{\beta-/-}$ hearts showed lower plateau $\lambda$ values compared to WT hearts, particularly with ageing. This would be consistent with the relative arrhythmic tendencies in the four experimental groups reported here. Further strengthening this hypothesis, the mean wavelengths immediately prior to termination of the protocol into either arrhythmia or 2:1 block were significantly different ($p = 0.01$) at $4.4 \pm 0.31$ ($n = 20$) for arrhythmic versus $5.4 \pm 0.20$ ($n = 68$) for non-arrhythmic hearts.

**Discussion**

The present study explored pro-arrhythmic phenotypes and their age-dependence in murine hearts deficient in the key mitochondrial upregulator, $Pgc-1^{\beta}$, previously associated with metabolic dysfunction. Previous molecular and cellular studies in murine $Pgc-1^{\beta-/-}$ cardiomyocytes had confirmed down-regulation of genes related to oxidative...
phosphorylation, electron transport and the Krebs cycle and upregulation of genes related to cardiac hypertrophy, hypoxia and heart failure [17]. Their fluorometric studies demonstrated cellular diastolic Ca$^{2+}$ transients, some forming Ca$^{2+}$ waves producing temporal and spatial Ca$^{2+}$ heterogeneities. Conventional patch clamp studies demonstrated positive voltage shifts in Ca$^{2+}$ current inactivation, increased Na$^{+}$, and transient and inwardly rectifying K$^{+}$ currents under conditions of intracellular Ca$^{2+}$ buffering. These findings together accompanied potentially pro-arrhythmogenic oscillatory resting potentials, early and delayed afterdepolarisations, and burst action potential firing on sustained current injection potentially related to AP alternans, and ventricular tachycardia [17].

| Table 3 | Areas under the curves (AUC) of AP parameter with respect to BCL |
|---------|---------------------------------------------------------------|
| Parameter | All WT | Young WT | Aged WT | All Young Pgc-1β$^{-/-}$ | Aged Pgc-1β$^{-/-}$ |
| (dV/dt)$_{max}$ (mV) | 87.19 ± 21.3 & 84.64 ± 31.5 & 86.44 ± 31.5 & 84.64 ± 31.5 & 86.44 ± 31.5 |
| APD$_{90}$ (ms) | 34.3 ± 9.7 & 34.3 ± 9.7 & 34.3 ± 9.7 & 34.3 ± 9.7 & 34.3 ± 9.7 |
| DI$_{90}$ (ms) | 3.45 ± 0.82 & 3.45 ± 0.82 & 3.45 ± 0.82 & 3.45 ± 0.82 & 3.45 ± 0.82 |
| RMP (mV) | -52.9 ± 5.4 & -52.9 ± 5.4 & -52.9 ± 5.4 & -52.9 ± 5.4 & -52.9 ± 5.4 |

Table represents the overall magnitude of each parameter across the different experimental categories. Values were obtained by calculating the area under the curves for each parameter in each heart and then means and standard errors calculated. Results of statistical tests are shown.

Fig. 6 Restitution plots of APD$_{90}$ against DI$_{90}$ (a) and of active AP wavelength (b) and passive wavelengths (c) observed at different BCLs through the incremental pacing procedure in young and aged WT and Pgc-1β$^{-/-}$ hearts.
These findings corroborated specifically for the $Pgc-1β^{−/−}$ model broader associations between energetic dysfunction and increased reactive oxygen species production [16], the latter affecting voltage-dependent Na⁺ and K⁺ current [32, 48], sarcolemmal K_ATP channel function, Na⁺ and Ca²⁺ channel inactivation, late Na⁺ current and ryanodine receptor function [19]. Finally, the accompanying ATP/ADP depletion is known to open sarcolemmal ATP-sensitive K⁺ channels (sarcK_ATP) [2].

Such changes potentially affect cell-cell coupling [43], AP conduction [32], repolarisation and refractoriness [48], and predispose to alternans and Ca²⁺-mediated pro-arrhythmic conduction [32], repolarisation and refractoriness [48], and occurred at lower pacing frequencies than in WT hearts, con- design

In (d V/dt)_{\text{max}} and AP latency, and shorter effective refractory periods than WT hearts. Furthermore, the onset of arrhythmia was associated with compromised AP activation but normal AP recovery.

These findings localise the arrhythmic substrate to defects in AP activation. $Pgc-1β^{−/−}$ hearts had altered AP wavelength (λ) properties, determined from the conduction velocity—effective refractory period product. Young and aged WT hearts showed similar λ-BCL and λ-λ₀ plots whereas young and aged $Pgc-1β^{−/−}$ hearts showed reduced values of λ through all BCLs—an effect more marked in the aged $Pgc-1β^{−/−}$ hearts. This finding is an exact parallel of previous demonstrations of the presence of arrhythmic phenotypes and of pro-arrhythmic alternans phenomena.

The present observations in $Pgc-1β^{−/−}$ hearts parallel features reported in $Scn5a^{−/−}$ and RyR2-P2328S/P2328S cardiac models for Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia, respectively [33–35, 39]. Recent work had similarly attributed arrhythmic substrate in RyR2-P2328S/P2328S hearts to slowed AP conduction accompanying reductions in (dV/dr)_{max} [53] and in Na⁺ currents to extents comparable to those observed in Na_{1.5}-haploinsufficient $Scn5a^{−/−}$ hearts [26, 27]. These reductions in Na⁺ currents in the RyR2-P2328S/P2328S cardiomyocytes were attributed to effects of altered Ca²⁺ homeostasis upon Na_{1.5} expression [39] and/or acutely upon Na_{1.5} function [26, 27]. RyR2-P2328S/P2328S and $Pgc-1β^{−/−}$ cardiomyocytes share abnormal Ca²⁺ handling phenotypes [17]. The normal or even enhanced Na⁺ currents in patch-clamped $Pgc-1β^{−/−}$ cardiomyocytes [17] are compatible with acute effects of their altered Ca²⁺ homeostasis upon membrane excitability in cardiomyocytes in intact tissue [26, 31, 39, 42]. Thus, patch-clamped WT myocytes also show respective acutely reduced, or increased, Na⁺ current and (dV/dr)_{max}, with increases in, or sequestration of, the pipette [Ca²⁺] [7]. These effects could reflect Ca²⁺-Na_{1.5} interactions involving direct Ca²⁺-Na_{1.5} binding at an EF hand motif close to the Na_{1.5} carboxy-terminal [50] or indirect Ca²⁺ binding involving an additional ‘IQ’ domain binding site for Ca²⁺/CaM in the Na_{1.5} C-terminal region [15, 37, 47]. The present findings thus throw light on possible, more widespread, effects of altered intracellular Ca²⁺ homeostasis on AP propagation in addition to identifying electrophysiological mechanisms underlying the arrhythmic risk associated with metabolic disturbance.

Acknowledgements We acknowledge the financial support from the Medical Research Council (MR/M001288/1); the Wellcome Trust (105727/Z/14/Z); the British Heart Foundation (PG/14/79/31102 and PG/15/12/31280); Sudden arrhythmic death syndrome (SADS) UK; The McVeigh Benefaction and by the Fundamental Research Grant Scheme (FRGS/2/2014/SKK01/PERDANA/02/1), Ministry of Education, Malaysia.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest.
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Adabag S, Huxley RR, Lopez FL, Chen LY, Sotoodehnia N, Siscovick D, Deo R, Konety S, Alonso A, Folsom AR (2015) Obesity related risk of sudden cardiac death in the atherosclerosis risk in communities study. Heart 101:215–221. doi:10.1136/heartjnl-2014-306238

2. Akar FG, O’Rourke B (2011) Mitochondria are sources of metabolic sink and arrhythmias. Pharmacol Ther 131:287–294. doi:10.1016/j.pharmthera.2011.04.005

3. Arany Z, He H, Lin J, Hoyer K, Handschin C, Toka O, Ahmad F, Matsui T, Chin S, Wu P-H, Rybkin IL, Shelton JM, Manieri M, Cinti S, Schoen FJ, Bassel-Duby R, Rosenzweig A, Ingwall JS, Spiegelman BM (2005) Transcriptional coactivator PGC-1 alpha controls the energy state and contractile function of cardiac muscle. Cell Metab 2(5):259–271. doi:10.1016/j.cmet.2005.03.002

4. Arany Z, Novikov M, Chin S, Ma Y, Rosenzweig A, Spiegelman BM (2006) Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc Natl Acad Sci U S A 103:10086–10091. doi:10.1073/pnas.0603615103

5. Balasubramaniam R, Chawla S, Mackenzie L, Schwiening CJ, Killeen MJ, Thomas G, Sabir IN, Grace AA, Huang CL-H (2005) Nifedipine and diltiazem suppress ventricular arrhythmogenesis and calcium release in mouse hearts. Pflugers Arch 449:150–155. doi:10.1007/s00424-004-1321-2

6. Balasubramaniam R, Chawla S, Grace AA, Huang CL-H (2004) Nifedipine and diltiazem suppress ventricular arrhythmogenesis in murine hearts. Acta Physiol 181:303–310. doi:10.1111/j.1748-1716.2004.01822.x

7. Casini S, Verkerk AO, van Borren MMGJ, van Ginneken ACG, Veldkamp MW, de Bakker JMT, Tan HL (2009) Intracellular calcium modulation of voltage-gated sodium channels in ventricular myocytes. Cardiovasc Res 81:72–81. doi:10.1093/cvr/cvn274

8. Deo R, Albert CM (2012) Epidemiology and genetics of sudden cardiac death. Circulation 125:620–637

9. Dillon LM, Rebolio AP, Moraes CT (2012) The role of PGC-1 coactivators in aging skeletal muscle and heart. IUBMB Life 64:231–241. doi:10.1007/s12238-012-9380-4

10. Dou Y, Arlock P, Aner A (2007) Blebbistatin specifically inhibits actin-myosin interaction in mouse cardiac muscle. Am J Physiol Cell Physiol 293:C1148–C1153. doi:10.1152/ajpcell.00551.2006

11. Farman GP, Tachampa K, Mateja R, Cazorla O, Lacampagne A, de Tombe PP (2008) Blebbistatin: use as inhibitor of muscle contraction. Pflugers Arch Eur J Physiol 455:995–1005. doi:10.1007/s00424-007-0375-3

12. Fedorov VV, Lozinsky IT, Sosunov EA, Anyukhovsky EP, Rosen MR, Balke CW, Efimov IR (2007) Application of blebbistatin as an excitation-contraction uncoupler for electrophysiologic study of rat and rabbit hearts. Hear Rhythm 4:619–626. doi:10.1016/j.hrthm.2006.12.047

13. Finck BN, Kelly DP (2006) PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J Clin Invest 116:615–622. doi:10.1172/JCI27794

14. Goddard CA, Ghais NS, Zhang Y, Williams AJ, Colledge WH, Grace AA, Huang CL-H (2008) Physiological consequences of the P2328S mutation in the rydorine receptor (RyR2) gene in genetically modified murine hearts. Acta Physiol 194:123–140. doi:10.1111/j.1748-1716.2008.01865.x

15. Grandi E, Herren AW (2014) CaMKII-dependent regulation of cardiac Na(+) homeostasis. Front Pharmacol 5:41. doi:10.3389/fphar.2014.00041

16. Grivnenkova VG, Kareyeva AV, Vinogradov AD (2010) What are the sources of hydrogen peroxide production by heart mitochondria? Biochim Biophys Acta 1797:939–944

17. Gurung IS, Medina-Gomez G, Kis A, Baker M, Velagapudi V, Neogi SG, Campbell M, Rodriguez-Cuenca S, Lelliott CJ, McFarlane I, Oresic M, Grace AA, Vidal-Puig A, Huang CL-H (2011) Deletion of the metabolic transcriptional coactivator PGC1β induces cardiac arrhythmia. Cardiovasc Res 92:29–38

18. Hatch F, Lancaster MK, Jones SA (2011) Aging is a primary risk factor for cardiac arrhythmias: disruption of intracellular Ca2+ regulation as a key suspect. Expert Rev Cardiovasc Ther 9:1059–1067. doi:10.1586/erc.11.112

19. Huang C (2017) Murine electrophysiological models of cardiac arrhythmogenesis. Physiol Rev 97:283–409

20. Huss JM, Imahashi K, Dufour CR, Weinheimer CJ, Courtois M, Kovacs A, Giguère V, Murphy E, Kelly DP (2007) The nuclear receptor ERα is required for the bioenergetic and functional adaption to cardiac pressure overload. Cell Metab 6:25–37. doi:10.1016/j.cmet.2007.06.005

21. Ingwall JS, Weiss RG (2004) Is the failing heart energy starved?: on using chemical energy to support cardiac function. Circ Res 95:135–145. doi:10.1161/01.RES.0000137170.41939.d9

22. Jeevaratnam K, Guzadur L, Goh Y, Grace AA, Huang CL-H (2016) Sodium channel haploinsufficiency and structural change in ventricular arrhythmogenesis. Acta Physiol 216:186–202. doi:10.1111/apha.12577

23. Jou CJ, Spitzer KW, Tristani-Firouzi M (2010) Blebbistatin effectively uncouples the excitation-contraction process in zebrafish embryonic heart. Cell Physiol Biochem 25:419–424. doi:10.1159/000303046

24. Kabunga P, Lau AK, Phan K, Puranik R, Liang C, Davis RL, Sue CM, Sy RW (2015) Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy. Int J Cardiol 181:303–310. doi:10.1016/j.ijcard.2014.12.038

25. Killeen MJ, Thomas G, Sabir IN, Grace AA, Huang CL-H (2008) Mouse models of human arrhythmia syndromes. Acta Physiol (Oxf) 192:455–469. doi:10.1111/j.1748-1716.2007.01822.x

26. King J, Wickramarachchi C, Kua K, Du Y, Jeevaratnam K, Matthews HR, Grace AA, Huang CL-H, Fraser JA (2013) Loss of Nav1.5 expression and function in murine atria containing the RyR2-P2328S gain-of-function mutation. Cardiovasc Res 99:751–759. doi:10.1093/cvr/cvr141

27. King J, Zhang Y, Lei M, Grace A, Huang C-H, Fraser J (2013) Atrial arrhythmia, triggering events and conduction abnormalities in isolated murine RyR2-P2328S hearts. Acta Physiol 207:308–323. doi:10.1111/apha.12006

28. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD (2010) Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Physiol 192:622–637. doi:10.1111/j.1748-1716.2010.01945.x

29. Kucharska-Newton AM, Couper DJ, Pankow JS, Prineas RJ, Rea TD, Sotoodehnia N, Chakravarti A, Folsom AR, Siscovick DS, Rosamond WD (2010) Diabetes and the risk of sudden cardiac death, the Atherosclerosis Risk in Communities study. Acta Physiol 192:622–637. doi:10.1111/j.1748-1716.2010.01945.x
30. Leone TC, Kelly DP (2011) Transcriptional control of cardiac fuel metabolism and mitochondrial function. Cold Spring Harb Symp Quant Biol 76:175–182. doi:10.1101/sqb.2011.76.011965
31. Li M, Hothi S, Salvage S, Jeevaratnam K, Grace A, Huang C (2017) Arrhythmic effects of Epac-mediated ryanodine receptor activation in Langendorff-perfused murine hearts are associated with reduced conduction velocity. Clin Exp Pharmacol Physiol 44:686–692
32. Liu M, Liu H, Dudley SC (2010) Reactive oxygen species originating from mitochondria regulate the cardiac sodium channel. Circ Res 107:967–974. doi:10.1161/CIRCRESAHA.110.220673
33. Matthews GDK, Guzadhur L, Grace A, Huang CL-H (2012) Nonlinearity between activation potential alternans and restitution, which both predict ventricular arrhythmic properties in Scn5a+/− and wild-type murine hearts. J Appl Physiol 112:1847–1863. doi:10.1152/japplphysiol.00039.2012
34. Matthews GDK, Guzadhur L, Sabir IN, Grace AA, Huang CL-H (2013) Activation potential wavelength restitution predicts alternans and arrhythmia in murine Scn5a+/− hearts. J Physiol 591:4167–4188. doi:10.1113/jphysiol.2013.254938
35. Matthews GDK, Martin CA, Grace AA, Zhang Y, Huang CL-H (2010) Regional variations in activation potential alternans in isolated murine Scn5a (+/−) hearts during dynamic pacing. Acta Physiol (Oxf) 200:129–146. doi:10.1111/j.1748-1716.2010.02138.x
36. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC (2003) PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34:267–273. doi:10.1038/ng1180
37. Mori M, Konno T, Ozawa T, Murata N, Inoko H, Nagayama K (2000) Novel interaction of the voltage-dependent sodium channel (VDSC) with calmodulin: does VDSC acquire calmodulin-mediated Ca(2+)-sensitivity? Biochemistry 39:1316–1323. doi:10.1021/bi9912600
38. Neubauer S (2007) The failing heart—an engine out of fuel. N Engl J Med 356:1140–1151. doi:10.1056/NEJMra063052
39. Ning F, Luo L, Ahmad S, Valli H, Jeevaratnam K, Wang T, Guzadhur L, Yang D, Fraser JA, Huang CL-H, Ma A, Salvage SC (2016) The RyR2-P2328S mutation downregulates Nav1.5 producing arrhythmic substrate in murine ventricles. Pflügers Arch Eur J Physiol 468:655–665. doi:10.1007/s00424-015-1750-x
40. R Core Team (2015) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna. ISBN: 3-900051-07-0. Available online at http://www.R-project.org/
41. Sabir IN, Li LM, Grace AA, Huang CL-H (2008) Restitutiation analysis of alternans and its relationship to arrhythmogenicity in hypokalaemic Langendorff-perfused murine hearts. Pflügers Arch Eur J Physiol 455:653–666. doi:10.1007/s00424-007-0327-y
42. Salvage SC, King JH, Chandrasekharan KH, Jafferji DIG, Guzadhur L, Matthews HR, Huang CL-H, Fraser JA (2015) Flecainide exerts paradoxical effects on sodium currents and atrial arrhythmia in murine RyR2-P2328S hearts. Acta Physiol 214:361–375. doi:10.1111/apha.12505
43. Smyth JW, Hong TT, Gao D, Vogan JM, Jensen BC, Fong TS, Simpson PC, Stainier DSY, Chi NC, Shaw RM (2010) Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium. J Clin Invest 120:266–279. doi:10.1172/JCI39740
44. Sonoda J, Mehl IR, Chong L-W, Nofisenger RR, Evans RM (2007) PGC-1β controls mitochondrial metabolism to modulate cardiovascular function, adaptive thermogenesis, and hepatic steatosis. Proc Natl Acad Sci U S A 104:5223–5228. doi:10.1073/pnas.0611261104
45. Terentyev D, Györke I, Belevyeh AE, Terentyeva R, Sridhar A, Nishijima Y, de Blanco EC, Khamna S, Sen CK, Cardonnel AJ, Carnes CA, Györke S (2008) Redox modification of ryanodine receptors contributes to sarcoplasmic reticulum Ca(2+) leak in chronic heart failure. Circ Res 103:1466–1472
46. Thomas G, Kileen MJ, Gurung IS, Hakim P, Balasubramaniam R, Goddard CA, Grace AA, Huang CL-H (2007) Mechanisms of ventricular arrhythmogenesis in mice following targeted disruption of KCNQ1 modelling long QT syndrome 5. J Physiol 578:99–114. doi:10.1113/jphysiol.2006.118133
47. Wagner S, Ruff HM, Weber SL, Bellmann S, Sowa T, Schulte T, Anderson ME, Grandi E, Bers DM, Backs J, Belardinelli L, Maier LS (2011) Reactive oxygen species-activated Ca/calmodulin kinase II δ is required for late I(Na) augmentation leading to cellular Na and Ca overload. Circ Res 108:555–565. doi:10.1161/CIRCRESAHA.110.221911
48. Wang J, Wang H, Zhang Y, Gao H, Nattel S, Wang Z (2004) Impairment of HERG K(+) channel function by tumor necrosis factor-alpha: role of reactive oxygen species as a mediator. J BiolChem 279:13289–13292
49. Wickham H (2009) ggplot2: elegant graphics for data analysis. Springer-Verlag, New York
50. Wingo TL, Shah VN, Anderson ME, Lybrand TP, Chazin WJ, Balser JR (2004) An EF-hand in the sodium channel couples intracellular calcium to cardiac excitability. Nat Struct Mol Biol 11:219–225. doi:10.1038/nsmb737
51. Yeung C-Y, Lam L-S-L, Li S-W, Lam K-F, Tsie H-F, Siu C-W (2012) Sudden cardiac death after myocardial infarction in type 2 diabetic patients with no residual myocardial ischemia. Diabetes Care 35:803–807. doi:10.23736/S0149-1995.11-17549-5